08:38 AM EDT, 07/23/2025 (MT Newswires) -- Revolution Medicines ( RVMD ) said Wednesday that its non-small cell lung cancer treatment elironrasib was granted breakthrough therapy designation by the US Food and Drug Administration.

Elironrasib is an inhibitor for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer who have received prior chemotherapy and immunotherapy but have not been previously treated with a KRAS G12C inhibitor, according to the company.

The designation is based on data from the phase 1 clinical trial assessing elironrasib monotherapy in patients with advanced KRAS G12C solid tumors, which showed "highly competitive antitumor activity, including differentiated safety and tolerability along with a compelling objective response rate and progression-free survival," the company said.

Shares were up 2.2% in recent premarket activity.